# TABLES

**Table 1. Baseline characteristics of patients (n=59)**

| Variable | Value |
|:----------|:---------|
| **Demographics** | |
| Age (years) | 70.1±8.2 |
| Female sex | 16 (22.0%) |
| **Cardiovascular risk factors** | |
| Hypertension | 39 (61.0%) |
| Diabetes mellitus | 24 (37.3%) |
| Hyperlipidemia | 43 (69.5%) |
| Previous MI | 16 (23.7%) |
| **Prior revascularization** | |
| Previous CABG | 2 (3.4%) |
| Previous PCI | 45 (76.3%) |
| **Clinical parameters** | |
| eGFR (mL/min/1.73m²) | 80.0 [64.0-91.0] |
| LVEF (%) | 60.0 [48.0-65.0] |
| **Clinical presentation** | |
| CCS | 55 (88.1%) |
| NSTEMI | 5 (6.8%) |
| STEMI | 2 (3.4%) |
| UA | 2 (1.7%) |

*Values are mean ± standard deviation, median [interquartile range], or n (%)*
CCS, chronic coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; UA, unstable angina; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction.

\newpage

**Table 2. Procedural characteristics of lesions (n=66)**

::: {custom-style="center"}
| Variable | Value |
|:----------|:---------|
| **Lesion characteristics** | |
| Baseline lesion length (mm) | 25.0 [15.0-30.0] |
| Baseline reference diameter (mm) | 2.5 [1.8-2.8] |
| SYNTAX score | 13.0 [7.0-16.0] |
| **Target vessel** | |
| LAD | 38 (64.4%) |
| RCA | 8 (13.6%) |
| LCX | 11 (18.6%) |
| **Lesion type** | |
| Bifurcation lesion | 21 (35.6%) |
| Chronic total occlusion | 15 (25.4%) |
| Severe calcification | 4 (11.8%) |
| **Predilatation balloon used** | |
| Semi-compliant balloon | 58 (88.0%) |
| Non-compliant balloon | 41 (62.0%) |
| Cutting balloon | 17 (28.8%) |
| Scoring balloon | 2 (3.4%) |
| OPN balloon | 1 (1.7%) |
| Shockwave | 3 (5.1%) |
| **DCB characteristics** | |
| DCB drug (paclitaxel) | 44 (77.2%) |
| DCB diameter (mm) | 2.5 [2.5-2.8] |
| DCB length (mm) | 25.0 [18.8-30.0] |
| DCB inflation time (s) | 60.0 [60.0-64.0] |
| DCB inflation pressure (atm) | 8.0 [6.0-10.0] |
| DCB diameter-to-vessel ratio | 1.1 [0.9-1.4] |
| **Pre-dilatation** | |
| Pre-dilatation balloon diameter (mm) | 3.0 [3.0-3.0] |
| Pre-dilatation balloon pressure (atm) | 16.0 [14.0-20.0] |
| **Procedural approach** | |
| Number of DCBs used | 0.9±0.8 |
| Hybrid PCI | 10 (16.9%) |
| **Antithrombotic therapy** | |
| - Prasugrel | 34 (51.5%) |
| - Clopidogrel | 32 (48.5%) |
| - Anticoagulant (DOAC) | 5 (7.6%) |
| Planned DAPT duration (months) | 6.0 [6.0-6.0] |
:::

*Values are mean ± standard deviation, median [interquartile range], or n (%).*
MLD, minimal lumen diameter; LAD, left anterior descending; RCA, right coronary artery; LCX, left circumflex; DCB, drug-coated balloon; OPN, optical pressure balloon; PCI, percutaneous coronary intervention; DAPT, dual antiplatelet therapy.

\newpage

**Table 3. Lesion evolution metrics (n=66)**

::: {custom-style="center"}
| Variable | All lesions |
|:----------|:----------|:----------|
| **MLD evolution (mm)** | | 
| Baseline MLD | 1.0 [0.5-1.4] | 
| Post-procedural MLD | 1.7 [1.4-1.9] | 
| Follow-up MLD | 1.7 [1.3-2.0] | 
| MLD acute gain | 0.5 [0.2-1.0] | 
| MLD late lumen change | 0.04 [-0.12-0.23] | 
| MLD net gain | 0.4 [-0.1-0.5] | 
| MLD acute recoil | 0.9 [0.6-1.2] | 
| MLD late recoil | 0.8 [0.6-1.3] | 
| **μFR evolution (%)** | | |
| Baseline μFR | 61.5 [23.8-76.3] | 
| Post-procedural μFR | 88.5 [81.0-92.0] | 
| Follow-up μFR | 91.0 [83.3-93.0] | 
| μFR acute functional gain | 12.0 [1.8-55.3] | 
| μFR late functional gain | 2.0 [-1.8-5.8] | 
| μFR net functional gain | 13.0 [5.0-45.8] | 
:::

*Values are median [interquartile range].*
MLD, minimal lumen diameter; μFR, microvascular fractional flow reserve; TLF, target lesion failure.

\newpage

**Table 4. Clinical outcomes at follow-up (n=66)**

::: {custom-style="center"}
| Outcome | n (%) |
|:----------|:----------|
| Target vessel failure | 8 (12.1%) |
| Target vessel myocardial infarction | 2 (3.0%) |
| Target lesion failure | 14 (21.2%) |
| Residual stenosis | 5 (100.0%) |
:::

